Therapeutic strategies for COVID-19: progress and lessons learned
G Li, R Hilgenfeld, R Whitley, E De Clercq - Nature Reviews Drug …, 2023 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
Structural biology of SARS-CoV-2: open the door for novel therapies
W Yan, Y Zheng, X Zeng, B He, W Cheng - Signal Transduction and …, 2022 - nature.com
Abstract Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is the causative
agent of the pandemic disease COVID-19, which is so far without efficacious treatment. The …
agent of the pandemic disease COVID-19, which is so far without efficacious treatment. The …
N501Y mutation of spike protein in SARS-CoV-2 strengthens its binding to receptor ACE2
SARS-CoV-2 has been spreading around the world for the past year. Recently, several
variants such as B. 1.1. 7 (alpha), B. 1.351 (beta), and P. 1 (gamma), which share a key …
variants such as B. 1.1. 7 (alpha), B. 1.351 (beta), and P. 1 (gamma), which share a key …
Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy
Q Zhang, R Xiang, S Huo, Y Zhou, S Jiang… - Signal transduction and …, 2021 - nature.com
The pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) infection has resulted in an unprecedented setback …
syndrome coronavirus 2 (SARS-CoV-2) infection has resulted in an unprecedented setback …
Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay
A Narayanan, M Narwal, SA Majowicz… - Communications …, 2022 - nature.com
SARS-CoV-2 proteases Mpro and PLpro are promising targets for antiviral drug
development. In this study, we present an antiviral screening strategy involving a novel in …
development. In this study, we present an antiviral screening strategy involving a novel in …
COVID-19 vaccines: The status and perspectives in delivery points of view
Due to the high prevalence and long incubation periods often without symptoms, the severe
acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has infected millions of individuals …
acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has infected millions of individuals …
Immunity, endothelial injury and complement-induced coagulopathy in COVID-19
In December 2019, a novel coronavirus was isolated from the respiratory epithelium of
patients with unexplained pneumonia in Wuhan, China. This pathogen, named severe acute …
patients with unexplained pneumonia in Wuhan, China. This pathogen, named severe acute …
The cytokine storm and COVID‐19
B Hu, S Huang, L Yin - Journal of medical virology, 2021 - Wiley Online Library
Abstract Coronavirus disease 2019 (COVID‐19), which began in Wuhan, China, in
December 2019, has caused a large global pandemic and poses a serious threat to public …
December 2019, has caused a large global pandemic and poses a serious threat to public …
The natural history, pathobiology, and clinical manifestations of SARS-CoV-2 infections
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological agent of
coronavirus disease 2019 (COVID-19). SARS-CoV-2, is a positive-sense single-stranded …
coronavirus disease 2019 (COVID-19). SARS-CoV-2, is a positive-sense single-stranded …
[HTML][HTML] Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach
The sudden emergence of severe respiratory disease, caused by a novel severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), has recently become a public health …
respiratory syndrome coronavirus 2 (SARS-CoV-2), has recently become a public health …